These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38253338)

  • 1. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
    Ison MG; Papi A; Athan E; Feldman RG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Verheust C; Dezutter N; Gruselle O; Fissette L; David MP; Kostanyan L; Hulstrøm V; Olivier A; Van der Wielen M; Descamps D;
    Clin Infect Dis; 2024 Jun; 78(6):1732-1744. PubMed ID: 38253338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
    Schwarz TF; Hwang SJ; Ylisastigui P; Liu CS; Takazawa K; Yono M; Ervin JE; Andrews CP; Fogarty C; Eckermann T; Collete D; de Heusch M; De Schrevel N; Salaun B; Lambert A; Maréchal C; Olivier A; Nakanwagi P; Lievens M; Hulstrøm V
    J Infect Dis; 2024 Jul; 230(1):e102-e110. PubMed ID: 39052726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
    Feldman RG; Antonelli-Incalzi R; Steenackers K; Lee DG; Papi A; Ison MG; Fissette L; David MP; Maréchal C; Van der Wielen M; Kostanyan L; Hulstrøm V;
    Clin Infect Dis; 2024 Jan; 78(1):202-209. PubMed ID: 37698366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
    Papi A; Ison MG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Campora L; Dezutter N; de Schrevel N; Fissette L; David MP; Van der Wielen M; Kostanyan L; Hulstrøm V;
    N Engl J Med; 2023 Feb; 388(7):595-608. PubMed ID: 36791160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.
    Kurai D; Mizukami A; Preckler V; Verelst F; Molnar D; Matsuki T; Ho Y; Igarashi A
    Expert Rev Vaccines; 2024; 23(1):303-311. PubMed ID: 38426479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    Leroux-Roels I; Van Ranst M; Vandermeulen C; Abeele CV; De Schrevel N; Salaun B; Verheust C; David MP; Kotb S; Hulstrøm V
    J Infect Dis; 2024 Feb; 229(2):355-366. PubMed ID: 37699064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.
    Falsey AR; Hosman T; Bastian AR; Vandenberghe S; Chan EKH; Douoguih M; Heijnen E; Comeaux CA; Callendret B;
    Lancet Infect Dis; 2024 Sep; 24(9):1015-1024. PubMed ID: 38801826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
    Curran D; Matthews S; Cabrera ES; Pérez SN; Breva LP; Rämet M; Helman L; Park DW; Schwarz TF; Melendez IMG; Schaefer A; Roy N; Stephan B; Molnar D; Kostanyan L; Powers JH; Hulstrøm V;
    Influenza Other Respir Viruses; 2024 Feb; 18(2):e13236. PubMed ID: 38314063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
    Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
    Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65.
    Buynak R; Cannon K; DeAtkine D; Kirby J; Usdan L; Bhavsar A; Gérard C; Kuznetsova A; Jayadev A; Amare H; Valenciano S; Meyer N
    Infect Dis Ther; 2024 Aug; 13(8):1789-1805. PubMed ID: 38981954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.
    Hermida N; Ferguson M; Leroux-Roels I; Pagnussat S; Yaplee D; Hua N; van den Steen P; Anspach B; Dieussaert I; Kim JH
    J Infect Dis; 2024 Aug; 230(2):e353-e362. PubMed ID: 38133639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
    Leroux-Roels I; Davis MG; Steenackers K; Essink B; Vandermeulen C; Fogarty C; Andrews CP; Kerwin E; David MP; Fissette L; Vanden Abeele C; Collete D; de Heusch M; Salaun B; De Schrevel N; Koch J; Verheust C; Dezutter N; Struyf F; Mesaros N; Tica J; Hulstrøm V
    J Infect Dis; 2023 Mar; 227(6):761-772. PubMed ID: 35904987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vaccines to prevent respiratory syncytial virus infection in infants and older adults: A systematic review and meta-analysis.
    Zeng B; Liu X; Yang Q; Wang J; Ren Q; Sun F
    Int J Infect Dis; 2024 Sep; 146():107118. PubMed ID: 38878994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.
    Ferguson M; Schwarz TF; Núñez SA; Rodríguez-García J; Mital M; Zala C; Schmitt B; Toursarkissian N; Mazarro DO; Großkopf J; Voors-Pette C; Mehta H; Hailemariam HA; de Heusch M; Salaun B; Damaso S; David MP; Descamps D; Hill J; Vandermeulen C; Hulstrøm V;
    Clin Infect Dis; 2024 Oct; 79(4):1074-1084. PubMed ID: 39099093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial.
    Chandler R; Montenegro N; Llorach C; Aguirre LN; Germain S; Kuriyakose SO; Lambert A; Descamps D; Olivier A; Hulstrøm V
    Clin Infect Dis; 2024 Jan; ():. PubMed ID: 38189778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.
    Dieussaert I; Hyung Kim J; Luik S; Seidl C; Pu W; Stegmann JU; Swamy GK; Webster P; Dormitzer PR
    N Engl J Med; 2024 Mar; 390(11):1009-1021. PubMed ID: 38477988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.
    Eto T; Okubo Y; Momose A; Tamura H; Zheng R; Callendret B; Bastian AR; Comeaux CA
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13336. PubMed ID: 38880785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Baker J; Aliabadi N; Munjal I; Jiang Q; Feng Y; Brock LG; Cooper D; Anderson AS; Swanson KA; Gruber WC; Gurtman A
    Vaccine; 2024 May; 42(13):3172-3179. PubMed ID: 38616438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.